Delving into the Latest Updates on Docosahexaenoic acid with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid, 22:6-4, 7,10,13,16,19, 4,7,10,13,16,19-docosahexaenoic acid

+ [17]

Target-

Action-

Mechanism-

Therapeutic Areas

NeoplasmsNervous System DiseasesCardiovascular Diseases+ [6]

Active Indication

Chronic Kidney DiseasesVision DisordersNon-Small Cell Lung Cancer+ [5]

Inactive Indication

Anemia, Sickle CellAttention Deficit DisorderHypertriglyceridemia

Originator Organization

DSM Biomedical, Inc.

Active Organization

Texas A&M UniversityVeterans Administration Medical Center

University of Nevada

+ [4]

Inactive Organization

Micelle BioPharma, Inc.StartupDSM Nutritional Products LLC

Sancilio & Co., Inc.

Drug Highest PhasePreclinical

First Approval Date-

RegulationOrphan Drug (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC22H32O2

InChIKeyMBMBGCFOFBJSGT-KUBAVDMBSA-N

CAS Registry6217-54-5

The goal of this study is to learn more about omega-3 polyunsaturated fatty acids supplementation on blood lipid profile and platelets in patients with high cholesterol levels.
The purpose of this research is to gather information on the safety and effect of two different fish oils, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
Participants will:
Visit the clinic 5 times during study checkups, tests and blood collection. Randomized to either the EPA or the DHA supplementation group. Be given a 28-day food and activity log.

Start Date01 Feb 2025

Sponsor / Collaborator

The Miriam Hospital

[+2]

CTRI/2024/11/076144

/ Not yet recruitingPhase 3IIT

Trial on effectiveness of omega 3 fatty acid supplements compared to Topical Steroids in Oral Lichen Planus Management - Nil

Start Date10 Nov 2024

Sponsor / Collaborator-

100 Clinical Results associated with Docosahexaenoic acid

Login to view more data

100 Translational Medicine associated with Docosahexaenoic acid

Login to view more data

100 Patents (Medical) associated with Docosahexaenoic acid

Login to view more data

49,290

Literatures (Medical) associated with Docosahexaenoic acid

31 Dec 2025·Journal of Maternal-Fetal & Neonatal Medicine

Evaluating the healing effects of docosahexaenoic acid in neonates with bilirubin-induced brain injury

Article

Author: Zhang, Jincan ; Hao, Wei ; Liu, Peng ; Li, Yuxia ; Pan, Li ; Wang, Jun ; Shao, Peng ; Tang, Yue

BACKGROUND:

Neonatal brain injury due to bilirubin toxicity presents critical need for effective healing treatments. Docosahexaenoic acid (DHA), having neuroprotective properties, offers potential therapeutic benefits in promoting brain repair and recovery.

OBJECTIVES:

This study focused on evaluating the healing capabilities of DHA in neonatal brains damaged by bilirubin-induced injury, with particular attention to its role in enhancing brain tissue repair mechanisms.

METHODS:

Employing the bilirubin encephalopathy model in neonatal Sprague-Dawley rats and neuronal cell cultures, we investigated the therapeutic impact of DHA.

RESULTS:

The study measured improvements in brain tissue integrity, assessed bilirubin levels, analyzed gene and protein expressions pertinent to the brain's recovery process. DHA administration resulted in significant repair in neonatal brains, evidenced by reduction in bilirubin levels and restoration of normal brain tissue architecture.

CONCLUSION:

Molecular analysis indicated the distinct modulation of the CTBP1/miR-155-5p/KDM5A pathway, critical for cellular repair processes and marked decrease in markers of cellular damage and stress.

31 Dec 2025·Journal of the International Society of Sports Nutrition

International Society of Sports Nutrition Position Stand: Long-Chain Omega-3 Polyunsaturated Fatty Acids

Review

Author: Kalman, Douglas S. ; Campbell, Bill I. ; Jäger, Ralf ; Dickerson, Broderick L. ; Cornish, Stephen M. ; Cordingley, Dean M. ; Leonard, Megan ; Heileson, Jeffery L. ; Forbes, Scott C. ; Bongiovanni, Tindaro ; Abou Sawan, Sidney ; Arent, Shawn M. ; Tinsley, Grant M. ; Kreider, Richard B. ; Kerksick, Chad M. ; Antonio, Jose ; Stout, Jeffrey R. ; Cannataro, Roberto ; Candow, Darren G.

Position Statement: The International Society of Sports Nutrition (ISSN) presents this position based on a critical examination of the literature surrounding the effects of long-chain omega-3 polyunsaturated fatty acid (ω-3 PUFA) supplementation on exercise performance, recovery, and brain health. This position stand is intended to provide a scientific foundation for athletes, dietitians, trainers, and other practitioners regarding the effects of supplemental ω-3 PUFA in healthy and athletic populations. The following conclusions represent the official position of the ISSN: Athletes may be at a higher risk for ω-3 PUFA insufficiency.Diets rich in ω-3 PUFA, including supplements, are effective strategies for increasing ω-3 PUFA levels.ω-3 PUFA supplementation, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), has been shown to enhance endurance capacity and cardiovascular function during aerobic-type exercise.ω-3 PUFA supplementation may not confer a muscle hypertrophic benefit in young adults.ω-3 PUFA supplementation in combination with resistance training may improve strength in a dose- and duration-dependent manner.ω-3 PUFA supplementation may decrease subjective measures of muscle soreness following intense exercise.ω-3 PUFA supplementation can positively affect various immune cell responses in athletic populations.Prophylactic ω-3 PUFA supplementation may offer neuroprotective benefits in athletes exposed to repeated head impacts.ω-3 PUFA supplementation is associated with improved sleep quality.ω-3 PUFA are classified as prebiotics; however, studies on the gut microbiome and gut health in athletes are currently lacking.

01 Dec 2025·Genes and Nutrition

Dietary polyunsaturated fatty acids affect PPARγ promoter methylation status and regulate the PPARγ/COX2 pathway in some colorectal cancer cell lines

Article

Author: Babaeenezhad, Esmaeel ; Khosravi, Peyman ; Moradi Sarabi, Mostafa

BACKGROUND:

Promoter methylation silencing of peroxisome proliferator-activated receptor gamma (PPARγ) and dysregulation of the PPARγ/COX2 axis contribute to colorectal cancer (CRC) pathogenesis. This study investigated for the first time the effects of dietary polyunsaturated fatty acids (PUFAs) on promoter methylation of PPARγ and the PPARγ/COX2 axis in five CRC cell lines.

METHODS:

Five CRC cell lines (SW742, HCT116, Caco2, LS180, and HT29/219) were treated with 100 µM of eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) or linoleic acid (LA). The methylation patterns of the four regions within the PPARγ promoter were determined using methylation-specific PCR (MSP). Additionally, the mRNA expression levels of PPARγ and COX2 were examined using RT-qPCR.

RESULTS:

Our results showed that M3 segment within the PPARγ promoter was hemimethylated in SW742 cells, whereas other cell lines remained unmethylated in this region. The M4 region was hemimethylated in all the CRC cell lines. Of all PUFAs, DHA demethylated the M3 region of the PPARγ promoter in SW742 cells and the M4 region in Caco2 cells. Functionally, these changes were accompanied by significant upregulation of PPARγ in SW742 (9.22-fold; p = 0.01) and Caco2 cells (8.87-fold; p = 0.04). Additionally, COX2 expression was significantly downregulated in all CRC cell lines after exposure to PUFAs (p < 0.05).

CONCLUSIONS:

This study demonstrated that PUFAs, particularly DHA, altered PPARγ promoter methylation and expression, as well as modulated the PPARγ/COX2 axis in CRC cells in a cell type-dependent manner. DHA was more effective than the other PUFAs in regulating PPARγ promoter methylation. Our results highlight the potential clinical use of PUFAs in CRC treatment.

70

News (Medical) associated with Docosahexaenoic acid

16 Aug 2024

·www.businesswire.com

Lobe Sciences Announces Creation of Wholly Owned Subsidiary, Alera Pharma, Inc.

VANCOUVER, British Columbia--( BUSINESS WIRE )-- Lobe Sciences, Ltd ("Lobe Sciences" or the "Company") (CSE: LOBE), (OTCQB: LOBEF) , a biopharmaceutical company focused on developing products to treat diseases with unmet medical needs, today announced that is has formed a wholly owned U.S. subsidiary named Alera Pharma, Inc. (Alera). Alera will be assigned the intellectual property rights focused on the Company’s neurological assets and its new chemical entity Psilocin Mucate. Mr. Rick Goulburn has been appointed as the Chief Executive Officer of Alera. Dr. Fred D. Sancilio will be Chairman of its Board of Directors and be joined on the board by Dr. Harry Jacobson, Mr. Wesley Ramjeet and Mr. Goulburn. Alera will be the operating company within the Lobe Sciences group focused on neurology and will join Altemia, LLC as the second operating subsidiary of Lobe Sciences. It is expected that the Company’s Australian subsidiary, Lobe Sciences Australia Pty Ltd., will become a subsidiary of Alera. Mr. Ilan Hayman will become a member of the executive management team of Alera. Dr. Sancilio, Chairman and CEO of Lobe Sciences said, “At present, Lobe Sciences has a complex corporate structure. By establishing Alera Pharma, we are simplifying the operations of the Company into just three entities. Lobe Sciences, Ltd will provide common services to the two operating subsidiaries - Alera and Altemia, LLC. The creation of two separate operating companies will allow each entity to create value within their respective therapeutic areas; neurology and hematology.” The Company also announces the receipt from the US PTO of a Notice of Allowance for its U.S. Patent Application Serial No. 18/411,576. About Lobe Sciences Ltd. Lobe Sciences is a biopharmaceutical company focused on developing medicines to treat diseases with unmet medical needs. The Company, through collaboration with industry-leading partners, is engaged in novel research and development focused on treating chronic cluster headache (an orphan disease), refractive anxiety, and sickle cell disease. The Company is engaged in Phase 1 and Phase 2 activities in its drug portfolio, and intends to initiate the launch of Altemia ® , a medical food designed to meet the needs of sickle cell patients globally. Cautionary Statement Regarding "Forward-Looking" Information This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including, without limitation: the composition of the management team of Alera and the ownership of Lobe Sciences Australia Pty Ltd., are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” or occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including, among other things, that: the management team of Alera will be appointed as currently expected and that Lobe Sciences Australia Pty Ltd. will become a subsidiary of Alera as currently anticipated. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that may cause actual results to vary, include, without limitation, the risk that: the management team of Alera will be appointed differently as currently expected and that Lobe Sciences Australia Pty Ltd. will not become a subsidiary of Alera as currently anticipated. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.

Executive ChangePhase 1Phase 2

19 Jul 2024

·www.drugs.com

Micronutrient Supplementation Slows Geographic Atrophy Progression

FRIDAY, July 19, 2024 -- Oral micronutrient supplementation slows geographic atrophy (GA) progression in age-related macular degeneration (AMD), according to a study published online July 16 in Ophthalmology . Tiarnan D.L. Keenan, B.M., B.Ch., Ph.D., from the National Institutes of Health in Bethesda, Maryland, and colleagues examined whether oral supplements slow GA progression in AMD in a post-hoc analysis of the Age-Related Eye Diseases Study (AREDS) and AREDS2 multicenter, randomized trials. A total of 392 eyes from 318 participants with GA were included in AREDS, and 1,210 eyes from 891 participants with GA were included in AREDS2. AREDS participants were randomly allocated to oral antioxidants; zinc (80 mg); combination; or placebo. AREDS2 participants were randomly assigned to lutein/zeaxanthin; docosahexaenoic acid/eicosapentaenoic acid; combination; or placebo. AREDS2 participants were also randomly assigned to alternative AREDS formulations: original, no β-carotene, zinc (25 mg), or both. The researchers found that proximity-based progression toward the central macula was significantly slower in AREDS eyes with noncentral GA with randomization to antioxidants versus none (50.7 versus 72.9 µm/year). In AREDS2 eyes with noncentral GA, proximity-based progression was significantly slower with randomization to lutein/zeaxanthin versus none among those assigned to AREDS antioxidants without β-carotene (80.1 versus 114.4 µm/year). Area-based progression was not significantly different with randomization to antioxidants versus none in AREDS2 eyes with any GA. "We've known for a long time that AREDS2 supplements help slow the progression from intermediate to late AMD. Our analysis shows that taking AREDS2 supplements can also slow disease progression in people with late dry AMD," Keenan said in a statement. "These findings support the continued use of AREDS2 supplements by people with late dry AMD." Several authors disclosed ties to the pharmaceutical industry.

Clinical Result

10 Jul 2024

·www.drugs.com

Adherence to Mediterranean Diet, Omega-3 Fatty Acids Beneficial in Acne

WEDNESDAY, July 10, 2024 -- Adherence to a Mediterranean diet incorporating eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) reduces skin lesions and improves quality of life in patients with acne, according to a study published online July 10 in the Journal of Cosmetic Dermatology . Anne Guertler, M.D., from Ludwig Maximilian University in Munich, and colleagues examined the clinical effects associated with increasing EPA/DHA levels in patients with acne. Sixty participants without prescription medication (23 with acne comedonica [AC] and 37 with acne papulopustulosa [AP]) adhered to a Mediterranean diet, incorporating omega-3 fatty acid supplementation. Blood EPA/DHA levels were tracked at four visits (V1 to V4) using the HS-omega 3 index (EPA/DHA [percent] of total identified fatty acids in erythrocytes: target, 8 to 11 percent; deficit, <8 percent; severe deficit, <4 percent). The researchers found that 98.3 percent of patients had an EPA/DHA deficit at baseline, with the mean HS-omega 3 index increasing from 4.9 to 8.3 percent at V1 to V4. At V4, significantly higher indices were seen for AC than AP. In both inflammatory and noninflammatory lesions, there were objective improvements observed. Four patients self-reported worsened appearance, but overall quality of life improved, especially in AP. Compared with beneficial foods, dietary triggers were more clearly defined. Cow's milk and dairy product intake was reduced. A high rate of compliance was observed, and there were no reports of adverse events. "Lifestyle interventions, including dietary recommendations, should not be considered in opposition to prescription medications, but rather as a valuable adjunct to any modern acne treatment plan," Guertler said in a statement. Omegametrix® GmbH performed the analysis of the HS-omega-3 Index® free of charge. Queisser Pharma GmbH & Co. KG offered omega-3 supplements free of charge.

Clinical Result

100 Deals associated with Docosahexaenoic acid

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Docosahexaenoic acid	V06D	DB03756

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Anemia, Sickle Cell	Phase 3	-	Micelle BioPharma, Inc.Startup	01 Mar 2019
Hypertriglyceridemia	Phase 3	-	Sancilio & Co., Inc.	28 Nov 2013
Attention Deficit Disorder	Phase 3	United States	DSM Nutritional Products LLC	01 Sep 2013
Chronic Kidney Diseases	Preclinical	Japan	Hiroshima University	13 Jun 2019
Vision Disorders	Preclinical	United States	Case Western Reserve University	07 May 2017
Non-Small Cell Lung Cancer	Preclinical	South Korea	Chungnam National University	15 Jul 2016
Coronary Disease	Preclinical	United States	Veterans Administration Medical Center	30 Oct 2012
Colorectal Cancer	Preclinical	United States	Texas A&M University	15 Apr 2010
Breast Cancer	Preclinical	United States	University of Nevada	01 May 2009
Adenocarcinoma of Lung	Preclinical	United States	University of Nevada	01 May 2008

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESC2024	Not Applicable	Cardiovascular Diseases	-	Eicosapentaenoic acid (EPA)	sasopziync(ntykkdzxwn) = nvgyspjoyd lkeopiplyg (qqcysjkrrh, 0.95 - 0.98)	-	02 Sep 2024
				Docosahexaenoic acid (DHA)	sasopziync(ntykkdzxwn) = gxamakwxyi lkeopiplyg (qqcysjkrrh, 0.86 - 0.89)
NCT01814527 (CTgov)	Not Applicable	Brain Concussion	62	Docosahexaenoic acid (Docosahexaenoic Acid)	jisseuqhlr(zejfsacafq) = upefgulobf wqtdiyikkh (mvjtklwbpq, kkyfuofjho - mqoqnaxnwu) View more	-	24 Apr 2024
				Placebo (Placebo)	jisseuqhlr(zejfsacafq) = vpebqwcruw wqtdiyikkh (mvjtklwbpq, zfsibhuykz - xcnruqjors) View more
NCT03965988 (Pubmed \| Pediatr Neurol)	Phase 3	Syncope	-	Docosahexaenoic Acid (DHA) plus Piracetam	dtnjhhgcwh(iiabttelwv) = gpmwenzfsu jkuykaqsfe (guooldvyhn )	Positive	01 Nov 2023
				Piracetam plus Placebo	dtnjhhgcwh(iiabttelwv) = nxevzxjohj jkuykaqsfe (guooldvyhn )
NCT03750968 (L-ZIP, CTgov)	Phase 2	Malnutrition	47	Carotenoid Group (Carotenoid Group)	rvxivgwrws(expdiragbr) = mdzmydirgu zxlwzgliww (hdnafkrzfb, 688) View more	-	11 Jul 2023
				Control Group (Control Group)	rvxivgwrws(expdiragbr) = mwddtctxhm zxlwzgliww (hdnafkrzfb, 470) View more
NCT01883817 (CTgov)	Phase 3	Attention Deficit Disorder	30	Placebo (Placebo)	pmnsgzuktp(hwerjlkvae) = zekrrmmzyt hpmwjacbjf (zlvtgabvln, 8.5) View more	-	16 Mar 2022
				DHA Omega-3 (DHA Omega-3)	pmnsgzuktp(hwerjlkvae) = anuztwtvqt hpmwjacbjf (zlvtgabvln, 6.6) View more
NCT01849250 (CTgov)	Phase 2	Triple Negative Breast Cancer \| Fibrocystic Breast Disease \| Invasive Mammary Carcinoma ... View more	65	Placebo (Placebo)	xsggbwvkeo(ruvdiwsyff) = jcbuzbfdgs mimtkowaax (szbukiopnp, 0.93) View more	-	28 Dec 2021
				Docosahexaenoic Acid (Docosahexaenoic Acid)	xsggbwvkeo(ruvdiwsyff) = cfubhwzvoy mimtkowaax (szbukiopnp, 0.78) View more
NCT03700957 (Pubmed \| Saudi Pharm J)	Not Applicable	Enterocolitis, Necrotizing	67	DHA group	nrkagugqlv(bsuqbgciii) = gbnueinutm egcsfyjqgg (iiwvnbbqtl )	-	01 Nov 2021
				Docosahexaenoic acid (Control group)	nrkagugqlv(bsuqbgciii) = icqfitcufk egcsfyjqgg (iiwvnbbqtl )
NCT03784963 (CTgov)	Phase 1/2	Gastrointestinal Hemorrhage \| Heart Failure	35	Omega 3 fatty acids (Primary Prevention Intervention)	hnvkolufcd(rntpxbtvhu) = xnqnqiuqle gtdudgfpgh (bmktylzehn, lylhgegtdf - owbnhldprj) View more	-	13 Jul 2021
				Placebo (Primary Prevention Non-Intervention)	hnvkolufcd(rntpxbtvhu) = yevwdncsyt gtdudgfpgh (bmktylzehn, eraotmkesx - xppsqppufj) View more
NCT02626299 (Pubmed)	Phase 3	Pregnancy \| Obstetric Labor, Premature	1,100	1000 mg DHA	wglcnbedug(fejcidcpkw) = qoinaasagl dyfsiplnrm (qwrdpnxhbm )	Positive	01 Jun 2021
				200 mg DHA	wglcnbedug(fejcidcpkw) = amufzxzhma dyfsiplnrm (qwrdpnxhbm )
NCT01502813 (CTgov)	Not Applicable	Cognition	40	Omega-3 Fatty Acids+Creatine+Citicoline	tkldgexucs(kthyhjthph) = fzfpyzuuii qemfpolpfb (drqihswxbk, boknqhpnkd - vilueaylad) View more	-	22 Apr 2021